StocksMedium•12 October 2026•
1 min read
Syndax Pharmaceuticals Axatilimab Phase 2 IPF Trial Fails Primary Endpoint
Key Facts
1The MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualized rate of decline in forced vital capacity (FVC).
2Axatilimab was well tolerated with a safety profile consistent with previous clinical studies and no new safety signals identified.
Syndax Pharmaceuticals announced that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint. GlobeNewswire reported that the trial failed to demonstrate a statistically significant improvement in the annualized rate of decline in forced vital capacity (FVC) compared to the placebo group.
Axatilimab was well tolerated during the 145-patient study, with a safety profile consistent with previous clinical trials and no new safety signals identified. In equity markets, SNDX closed at $16.99 on October 9, 2026, having traded between a day low of $16.78 and a high of $17.42 during that session.